经颈静脉肝内门体分流术预防肝硬化门静脉高压患者进一步失代偿并改善生存:个体患者数据Meta分析
该个体患者数据Meta分析纳入2004至2020年12项对照研究共3949例患者,经倾向性评分匹配后分析2338例(标准治疗1749例,TIPS 589例)。TIPS组2年进一步失代偿累积发生率低于标准治疗组,2年累积生存概率高于标准治疗组;调整后个体患者数据Meta分析证实TIPS降低进一步失代偿风险(HR 0.44)。
要点
- TIPS组2年进一步失代偿累积发生率0.48,低于标准治疗组的0.63。
- 调整后个体患者数据Meta分析显示TIPS与进一步失代偿风险降低相关(HR 0.44,95%CI 0.37-0.54)。
- TIPS组2年累积生存概率0.71,高于标准治疗组的0.63。
核心结论
- 对于难治性腹水和预防静脉曲张再出血,TIPS较标准治疗降低进一步失代偿事件发生率并提高生存率,适用于经过高度选择的患者。
研究设计与样本
- 个体患者数据Meta分析,纳入2004至2020年发表的比较覆膜TIPS与标准治疗的对照研究,共从12项对照研究中提取3949例个体患者数据。
- 经倾向性评分匹配后分析2338例特征相似的患者(标准治疗组1749例,TIPS组589例)。
- 主要结局为进一步失代偿发生率,次要结局为总生存率。
主要发现
- 倾向性评分匹配人群中,TIPS组2年进一步失代偿累积发生率函数为0.48(95%CI 0.43-0.52),标准治疗组为0.63(95%CI 0.61-0.65),分层Gray检验p<0.0001,将死亡和肝移植作为竞争事件。
- 调整后个体患者数据Meta分析证实TIPS组进一步失代偿率更低(风险比0.44;95%CI 0.37-0.54),且在TIPS适应证各亚组间一致。
- TIPS组2年累积生存概率高于标准治疗组(0.71 vs 0.63;p=0.0001)。
临床怎么用
- 作者结论认为,对难治性腹水和预防静脉曲张再出血使用TIPS可较标准治疗降低进一步失代偿事件发生率并提高生存率,适用于经过高度选择的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Further decompensation represents a prognostic stage of cirrhosis associated with higher mortality compared with first decompensation. A transjugular intrahepatic portosystemic shunt (TIPS) is indicated to prevent variceal rebleeding and for refractory ascites, but its overall efficacy to prevent further decompensations is unknown. This study assessed the incidence of further decompensation and mortality after TIPS vs. standard of care (SOC). METHODS: Controlled studies assessing covered TIPS compared with SOC for the indication of refractory ascites and prevention of variceal rebleeding published from 2004 to 2020 were considered. We collected individual patient data (IPD) to perform an IPD meta-analysis and to compare the treatment effect in a propensity score (PS)-matched population. Primary outcome was the incidence of further decompensation and the secondary outcome was overall survival. RESULTS: In total, 3,949 individual patient data sets were extracted from 12 controlled studies and, after PS matching, 2,338 patients with similar characteristics (SOC = 1,749; TIPS = 589) were analysed. The 2-year cumulative incidence function of further decompensation in the PS-matched population was 0.48 (95% CI 0.43-0.52) in the TIPS group vs. 0.63 (95% CI 0.61-0.65) in the SOC group (stratified Gray's test, p <0.0001), considering mortality and liver transplantation as competing events. The lower further decompensation rate with TIPS was confirmed by adjusted IPD meta-analysis (hazard ratio 0.44; 95% CI 0.37-0.54) and was consistent across TIPS indication subgroups. The 2-year cumulative survival probability was higher with TIPS than with SOC (0.71 vs. 0.63; p = 0.0001). CONCLUSIONS: The use of TIPS for refractory ascites and for prevention of variceal rebleeding reduces the incidence of a further decompensation event compared with SOC and increases survival in highly selected patients. IMPACT AND IMPLICATIONS: A further decompensation (new or worsening ascites, variceal bleeding or rebleeding, hepatic encephalopathy, jaundice, hepatorenal syndrome-acute kidney injury and spontaneous bacterial peritonitis) in patients with cirrhosis is associated with a poor prognosis. Besides the known role of TIPS in portal hypertension-related complications, this study shows that TIPS is also able to decrease the overall risk of a further decompensation and increase survival compared with standard of care. These results further support the role of TIPS in the management of patients with cirrhosis and portal hypertension-related complications.
引用
- Larrue H, D'Amico G, Olivas P, et al. TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis. J Hepatol. 2023. PMID: 37141993. doi:10.1016/j.jhep.2023.04.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。